Congress Materials – American Association for Cancer Research (AACR 2025)
2025 American Association for Cancer Research | Apr 25-30 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Phase 2b Study of Subcutaneous Amivantamab With Lazertinib as First-Line Treatment, or With Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-small Cell Lung Cancer (NSCLC): COPERNICUS
Balazs Halmos, Narjust Florez, Sarah Goldberg, Wade Iams, Xiuning Le, Ticiana Leal, Danny Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua Sabari, David Bjork, Nichelle Stigger, Yichuan Xia, Paul Cifuentes, Denise D’Andrea, Andy L. Johnson, Melissa L. Johnson
This document will be available on April 29 2025
AmoyDx Essential NGS Panel (LC 10), One Solution Covering Tumor Tissue and Plasma for Detection of EGFR and cMET Alterations in NSCLC
Min Qing, Jingxun Wu, Yuping Li, Jianmin Li, Xing Li, Cheng Li, Yin Shi, Xuejun Chen, Zhenjun Tan, Xiaofang Zhuo, Chengjuan Xiong, Longen Zhou, Flora Berisha, Changbin Zhu
This document will be available on April 27 2025
Discovery of WRN Helicase Inhibitors that Covalently Engage a Novel, Induced Allosteric Site
Francis W. Hunter, Lindsey DeRatt, Kenneth Maksimchuk, Tatsuya Maehigashi, Seong Joo Koo, Liesbeth Micholt, Ranjeet P. Dash, Faraz Kazmi, Zhengyu Jiang, Albi Francis, Neetu Shukla, Aaron Patrick, Trpta Bains, Romy Perez-Abraham, Nikit Kumar, Zhijie Liu, Brian Reiss, Caitlin Morgan, Inha Heo, Werner Eyckmans, Gerald Chu, Anna Kuhn, Lorraine Angelillo, Lin-Chien Huang, Yu Sun, Ashley M. Rouleau, Yongkang Kim, John J. H. Shin, Harris Bell-Temin, Victoria Wong, Ruth Steele, Paul Shaffer, Kurtis E. Bachman, David Pocalyko, Scott Kuduk
This document will be available on April 29 2025
Establishing Optimal Care Coordination in Localized Bladder Cancer in the United States: A Modified Delphi Consensus Study
Gautam Jayram, Monica Baskin, Gordon Brown, Mollie Deshazo, Michael Fabrizio, Hiremagalur Balaji, Angela Hunter, Mukul Singhal, Arveen Kaur, Mike Lattanzi, Lynn Redmond, Guru Sonpavde
This document will be available on April 29 2025
Extending ENPP3 Expression Inference From Tissue Microarrays to Whole Tissue Sections: Building a Case fro Automated Patient Enrichment and IHC Scoring
Erik Ames Burlingame, Fatemeh Koochaki, Tsun-Wen Sheena Yao, Shajo Kunnath-Velayudhan, Kristopher Standish, Albert Juan Ramon
This document will be available on April 28 2025
Geographic and Racial Disparities in Bladder Cancer Care in the U.S.
Atreyee Majumder, Daniel Erim, Arveen Kaur, Lisa Dwyer Orr
This document will be available on April 28 2025
Initial Results From a Phase 1 Study of an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Anti-PD1 Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Prantesh Jain, Alexander Spira, Seehoon Lee, Byoung Chul Cho, Enriqueta Felip, Andres Aguilar, Sarah Gordon, Sebastian Ochsenreither, Thomas Wehler, Amanda McGillivray, Ariel Chen, Raja Venkatasubramanian, Rajesh Bandekar, Shu Jin, Rosa Martín-Pérez, Aisha Nasreen Hasan, Brian Henick
This document will be available on April 29 2025
Mechanisms of Acquired Resistance and ctDNA Clearance in EGFR-Mutated Advanced NSCLC Following Lazertinib Treatment: Results From the Phase 3 LASER301 Study
Byoung Chul Cho, Ki Hyeong Lee, Chin Heng Fong, Anastasia Zimina, Yong Kek Pang, Sergey Orlov, Joo-Hang Kim, Jason K Sa, YuKyung Kim, Mi-Jung Kwon, SeokYoung Choi, Dongmin Kim, Min Kim, Myung-Ju Ahn
This Alliance document will be available on April 28 2025
PRMT5 as a Target in CRC Interception: Synthetic Lethal Dependency Identified in APC-LOF Preclinical Models of FAP Disease
Dana S. Gaffney, Jan Willem Thuring, Fabian Hulpia, Eileen Vesely, Edward Retzbach, Zienab Etwebi, Zhengyu Jiang, Albi Francis, Bethany Mattson, Victoria Wong, Mariana Silva, Gerben Ten Hag, Rene Overmeer, Carla Verissimo, Sylvia F. Boj, Johan Nicolai, Mark Hixon, Gerry Chu, Andrea DiSandro, Kathleen Clancy, Alexandra Liddane, Kurtis Bachman, David Pocalyko
This document will be available on April 28 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.